| Identifier |
20230314_nanos_posters_296 |
| Title |
THRIVE: A Phase 3 Trial of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED) |
| Creator |
Barrett Katz; Rochelle Summerfelt; Denis O'Shaughnessy |
| Affiliation |
(BK) (RS) (DO) Viridian Therapeutics Inc. |
| Subject |
Graves' Disease; Neuro-ophth & Systemic Disease (eg. MS, MG, Thyroid); Orbit/ocular Pathology |
| Description |
VRDN-001, a full antagonist antibody to the IGF-1 receptor (IGF-1R), is in development for treatment of TED. Initial results in patients with moderate-to-severe active TED demonstrated clinically meaningful improvements in proptosis, inflammation, and diplopia at 6 weeks, after 2 infusions of 10 mg/kg VRDN-001. THRIVE is a doublemasked, placebo-controlled phase 3 trial to confirm and extend these results. |
| Date |
2023-03-14 |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of |
NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
| Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
| Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6zvp1fm |
| Setname |
ehsl_novel_nam |
| ID |
2335501 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6zvp1fm |
